Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628596 | 0.91 | FNTA (0.98) | FNTAFNTB | |
| Lithium SCHEMBL6628599 | 0.91 | FNTA (0.98) | FNTAFNTB | |
| SCHEMBL7871129 | 0.90 | FNTA (0.85) | FNTAFNTB | |
| SCHEMBL7871133 | 0.90 | FNTA (0.85) | FNTAFNTB | |
| SCHEMBL6627300 | 0.80 | FNTA (0.79) | FNTAFNTB | |
| SCHEMBL6627296 | 0.80 | FNTA (0.79) | FNTAFNTB | |
| Hydrochloric Acid SCHEMBL7870253 | 0.80 | FNTA (0.78) | FNTAFNTB | |
| Hydrochloric Acid SCHEMBL7870250 | 0.80 | FNTA (0.78) | FNTAFNTB | |
| Lithium Ion SCHEMBL7869115 | 0.79 | FNTA (0.57) | FNTAFNTB | |
| Lithium Ion SCHEMBL7903863 | 0.77 | FNTA (0.69) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986384-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2004-09-15 | — | — | EP | claimed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | claimed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |